PYC Thera. (PYC) is held by 5 ASX ETFs. Over all time it rose 142.9%: on $10,000, +$14286. We explain 12 big moves in that time.
About PYC
- SectorHealth Care
- IndustryPharmaceuticals, Biotechnology & Life Sciences
- Size$2.5b
- Held by5 ETFs
- Big moves12 in all time
Each dot is a move we explain. Tap one, or a row of Why it moved, to see what caused it.
Why it moved
- +7.9%18 Sep 2026· Contract
PYC Therapeutics rose on momentum from a clinical milestone — dosing the first patient in its PKD open-label extension study — amplified by a run of bullish media coverage highlighting strong recent share price performance and pipeline progress.
- +6.1%2 Sep 2026· Earnings Beat
PYC Therapeutics shares rose after its full-year results showed a narrowed net loss, which was received positively by the market in the days following the annual report release.
- −5.9%21 Aug 2026· Sector Flow
PYC Therapeutics fell alongside a broad sell-off in the Australian healthcare sector, with no company-specific news to explain the move.
- +9.6%4 Aug 2026· Operational
PYC Therapeutics shares rose 9.62% on August 4, 2026, as the company's kidney trial advanced into multiple dosing, attracting investor attention.
- +6.2%3 Aug 2026· Sector Flow
PYC Therapeutics rose in line with a broad healthcare sector rally on the ASX, which was up over 2.3% on the same day.
- +7.9%13 May 2026· Unknown
No specific news was found; the price move is unexplained with available data.
- +5.5%13 May 2026· Unknown
No specific news articles were found to explain the price movement, so the cause remains unidentified.
- +5.9%1 Apr 2026· Sector Flow
Biotech sector selloff in March likely caused a modest rebound for PYC Therapeutics, with no stock-specific news.
- −6.0%27 Mar 2026· Unknown
No specific company news explains the move; likely market-wide sector or macro-driven selling pressure.
- +16.2%22 Sep 2025· Unknown
No direct cause identified; news article references a different company (Starpharma), not PYC Therapeutics.
- −30.0%17 Sep 2025· Management
PYC Therapeutics' CEO Rohan Hockings abruptly quit, triggering a leadership transition and a sharp stock selloff.
- +16.1%26 Sep 2024· Unknown
Insufficient evidence to determine the cause of the price move
Held by 5 ETFs
Of every $10,000 in each fund, how much is in PYC today.
Why did PYC rise 16.1% on 26 Sep 2024?
PYC Thera.
Insufficient evidence to determine the cause of the price move
No news articles or announcements were found around the event date to explain the abnormal price increase. The move is significant (16.13% with 6x ATR multiple), but without any public information, I cannot attribute it to a specific driver.
General information only, not personal advice — prepared without regard to your objectives, financial situation or needs. Past performance is not indicative of future performance.
No evidence layer produced anything for this event.
What it did to the 5 ETFs holding PYC
On $10,000 in each fund, at the weight it holds today